JAK2 activation by growth hormone and other cytokines

Biochemical Journal

Volumn 466, Issue , 2015, Pages 1-11

  Waters, Michael J ^a   Brooks, Andrew J ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Class I cytokine receptors; Cytokine receptor signalling; Growth hormone; Growth hormone receptor; Janus kinase 2 (JAK2); Srk family kinases

Indexed keywords

BINDING PROTEIN; CYTOKINE RECEPTOR; GROWTH HORMONE; HOMODIMER; JANUS KINASE 2; RECEPTOR SUBUNIT; STAT PROTEIN; CYTOKINE; GROWTH HORMONE RECEPTOR; JAK2 PROTEIN, HUMAN; PROTEIN BINDING;

BINDING AFFINITY; CELL ACTIVATION; CELL MEMBRANE; CHEMICAL ANALYSIS; CLINICAL TRIAL (TOPIC); CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; CYTOPLASM; DIMERIZATION; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; LIGAND BINDING; MOLECULAR DYNAMICS; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PHYSIOLOGICAL PROCESS; POSTNATAL GROWTH; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; STEM CELL; ANIMAL; CHEMICAL STRUCTURE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PROTEIN DOMAIN; PROTEIN MULTIMERIZATION;

ANIMALS; CYTOKINES; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; GROWTH HORMONE; HUMANS; JANUS KINASE 2; MODELS, MOLECULAR; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN MULTIMERIZATION; RECEPTOR CROSS-TALK; RECEPTORS, CYTOKINE; RECEPTORS, SOMATOTROPIN; SIGNAL TRANSDUCTION;

EID: 84922335259     PISSN: 02646021     EISSN: 14708728     Source Type: Journal    
DOI: 10.1042/BJ20141293     Document Type: Review

References (118)

1. Babon, J. J., Varghese, L. N. and Nicola, N. A. (2014) Inhibition of IL-6 family cytokines by SOCS3. Semin. Immunol. 26, 13-19 CrossRef PubMed
2. O'Sullivan, L. A., Liongue, C., Lewis, R. S., Stephenson, S. E. and Ward, A. C. (2007) Cytokine receptor signaling through the Jak-Stat-Socs pathway in disease. Mol. Immunol. 44, 2497-2506 CrossRef PubMed
3. Chhabra, Y., Waters, M. J. and Brooks, A. J. (2011) Role of the growth hormone-IGF-1axis in cancer. Expert Rev. Endocrinol. Metab. 6, 71-84 CrossRef
4. Hercus, T. R., Dhagat, U., Kan, W. L., Broughton, S. E., Nero, T. L., Perugini, M., Sandow, J. J., D'Andrea, R. J., Ekert, P. G., Hughes, T. et al. (2013) Signalling by the betac family of cytokines. Cytokine Growth Fact. Rev. 24, 189-201 CrossRef
5. Silver, J. S. and Hunter, C. A. (2010) gp130 at the nexus of inflammation, autoimmunity, and cancer. J. Leukocyte Biol. 88, 1145-1156 CrossRef
6. Scott, L. M. (2013) Lymphoid malignancies: Another face to the Janus kinases. Blood Rev. 27, 63-70 CrossRef PubMed
7. Beer, P. A., Campbell, P. J., Scott, L. M., Bench, A. J., Erber, W. N., Bareford, D., Wilkins, B. S., Reilly, J. T., Hasselbalch, H. C., Bowman, R. et al. (2008) MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood 112, 141-149CrossRef PubMed
8. Goffin, V., Hoang, D. T., Bogorad, R. L. and Nevalainen, M. T. (2011) Prolactin regulation of the prostate gland: a female player in a male game. Nat. Rev. Urol. 8, 597-607CrossRef PubMed
9. Rawlings, J. S., Rosler, K. M. and Harrison, D. A. (2004) The JAK/STAT signaling pathway. J. Cell Sci. 117, 1281-1283 CrossRef PubMed
10. Brooks, A. J. and Waters, M. J. (2010) The growth hormone receptor: mechanism of activation and clinical implications. Nat. Rev. Endocrinol. 6, 515-525 CrossRef PubMed
11. Bazan, J. F. (1990) Structural design and molecular evolution of a cytokine receptor superfamily. Proc. Natl. Acad. Sci. U.S.A. 87, 6934-6938 CrossRef PubMed
12. Olsen, J. G. and Kragelund, B. B. (2014) Who climbs the tryptophan ladder? On the structure and function of the WSXWS motif in cytokine receptors and thrombospondin repeats. Cytokine Growth Fact. Rev. 25, 337-341 CrossRef
13. Liongue, C. and Ward, A. C. (2007) Evolution of Class I cytokine receptors. BMC Evol. Biol. 7, 120 CrossRef PubMed
14. de Vos, A. M., Ultsch, M. and Kossiakoff, A. A. (1992) Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. Science 255, 306-312 CrossRef PubMed
15. Broutin, I., Jomain, J. B., Tallet, E., van Agthoven, J., Raynal, B., Hoos, S., Kragelund, B. B., Kelly, P. A., Ducruix, A., England, P. and Goffin, V. (2010) Crystal structure of an affinity-matured prolactin complexed to its dimerized receptor reveals the topology of hormone binding site 2. J. Biol. Chem. 285, 8422-8433 CrossRef PubMed
16. Livnah, O., Stura, E. A., Johnson, D. L., Middleton, S. A., Mulcahy, L. S., Wrighton, N. C., Dower, W. J., Jolliffe, L. K. and Wilson, I. A. (1996) Functional mimicry of a protein hormone by a peptide agonist: the EPO receptor complex at 2.8 A. Science 273, 464-471 CrossRef PubMed
17. Cunningham, B. C., Ultsch, M., De Vos, A. M., Mulkerrin, M. G., Clauser, K. R. and Wells, J. A. (1991) Dimerization of the extracellular domain of the human growth hormone receptor by a single hormone molecule. Science 254, 821-825CrossRef PubMed
18. van Agthoven, J., Zhang, C., Tallet, E., Raynal, B., Hoos, S., Baron, B., England, P., Goffin, V. and Broutin, I. (2010) Structural characterization of the stem-stem dimerization interface between prolactin receptor chains complexed with the natural hormone. J. Mol. Biol. 404, 112-126 CrossRef PubMed
19. Syed, R. S., Reid, S. W., Li, C., Cheetham, J. C., Aoki, K. H., Liu, B., Zhan, H., Osslund, T. D., Chirino, A. J., Zhang, J. et al. (1998) Efficiency of signalling through cytokine receptors depends critically on receptor orientation. Nature 395, 511-516CrossRef PubMed
20. Matthews, D. J., Topping, R. S., Cass, R. T. and Giebel, L. B. (1996) A sequential dimerization mechanism for erythropoietin receptor activation. Proc. Natl. Acad. Sci. U.S.A. 93, 9471-9476 CrossRef PubMed
21. Chen, C., Brinkworth, R. and Waters, M. J. (1997) The role of receptor dimerization domain residues in growth hormone signaling. J. Biol. Chem. 272, 5133-5140CrossRef PubMed
22. Harrison, S. M., Barnard, R., Ho, K. Y., Rajkovic, I. and Waters, M. J. (1995) Control of growth hormone (GH) binding protein release from human hepatoma cells expressing full-length GH receptor. Endocrinology 136, 651-659 PubMed
23. Frank, S. J., Gilliland, G., Kraft, A. S. and Arnold, C. S. (1994) Interaction of the growth hormone receptor cytoplasmic domain with the JAK2 tyrosine kinase. Endocrinology 135, 2228-2239 PubMed
24. Jiang, N., He, T. C., Miyajima, A. and Wojchowski, D. M. (1996) The box1 domain of the erythropoietin receptor specifies Janus kinase 2 activation and functions mitogenically within an interleukin 2 beta-receptor chimera. J. Biol. Chem. 271, 16472-16476CrossRef PubMed
25. Watanabe, S., Itoh, T. and Arai, K. (1996) JAK2 is essential for activation of c-fos and c-myc promoters and cell proliferation through the human granulocyte-macrophage colony-stimulating factor receptor in BA/F3 cells. J. Biol. Chem. 271, 12681-12686CrossRef PubMed
26. Pelletier, S., Gingras, S., Funakoshi-Tago, M., Howell, S. and Ihle, J. N. (2006) Two domains of the erythropoietin receptor are sufficient for Jak2 binding/activation and function. Mol. Cell. Biol. 26, 8527-8538 CrossRef PubMed
27. Lebrun, J. J., Ali, S., Ullrich, A. and Kelly, P. A. (1995) Proline-rich sequence-mediated Jak2 association to the prolactin receptor is required but not sufficient for signal transduction. J. Biol. Chem. 270, 10664-10670 CrossRef PubMed
28. Hansen, G., Hercus, T. R., McClure, B. J., Stomski, F. C., Dottore, M., Powell, J., Ramshaw, H., Woodcock, J. M., Xu, Y., Guthridge, M., McKinstry, W. J., Lopez, A. F. and Parker, M. W. (2008) The structure of the GM-CSF receptor complex reveals a distinct mode of cytokine receptor activation. Cell 134, 496-507 CrossRef PubMed
29. Broughton, S. E., Hercus, T. R., Hardy, M. P., McClure, B. J., Nero, T. L., Dottore, M., Huynh, H., Braley, H., Barry, E. F., Kan, W. L. et al. (2014) Dual mechanism of interleukin-3 receptor blockade by an anti-cancer antibody. Cell Rep. 8, 410-419CrossRef PubMed
30. Boulanger, M. J., Chow, D. C., Brevnova, E. E. and Garcia, K. C. (2003) Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex. Science 300, 2101-2104 CrossRef PubMed
31. Skiniotis, G., Boulanger, M. J., Garcia, K. C. and Walz, T. (2005) Signaling conformations of the tall cytokine receptor gp130 when in complex with IL-6 and IL-6 receptor. Nat. Struct. Mol. Biol. 12, 545-551 CrossRef PubMed
32. Huyton, T., Zhang, J. G., Luo, C. S., Lou, M. Z., Hilton, D. J., Nicola, N. A. and Garrett, T. P. (2007) An unusual cytokine:Ig-domain interaction revealed in the crystal structure of leukemia inhibitory factor (LIF) in complex with the LIF receptor. Proc. Natl. Acad. Sci. U.S.A. 104, 12737-12742 CrossRef PubMed
33. Skiniotis, G., Lupardus, P. J., Martick, M., Walz, T. and Garcia, K. C. (2008) Structural organization of a full-length gp130/LIF-R cytokine receptor transmembrane complex. Mol. Cell 31, 737-748 CrossRef PubMed
34. Nicola, N. A. and Hilton, D. J. (1998) General classes and functions of four-helix bundle cytokines. Adv. Protein Chem. 52, 1-65 CrossRef PubMed
35. Wells, J. A. (1996) Binding in the growth hormone receptor complex. Proc. Natl. Acad. Sci. U.S.A. 93, 1-6 CrossRef PubMed
36. Fuh, G., Cunningham, B. C., Fukunaga, R., Nagata, S., Goeddel, D. V. and Wells, J. A. (1992) Rational design of potent antagonists to the human growth hormone receptor. Science 256, 1677-1680 CrossRef PubMed
37. Leung, D. W., Spencer, S. A., Cachianes, G., Hammonds, R. G., Collins, C., Henzel, W. J., Barnard, R., Waters, M. J. and Wood, W. I. (1987) Growth hormone receptor and serum binding protein: purification, cloning and expression. Nature 330, 537-543CrossRef PubMed
38. Rowlinson, S. W., Behncken, S. N., Rowland, J. E., Clarkson, R. W., Strasburger, C. J., Wu, Z., Baumbach, W. and Waters, M. J. (1998) Activation of chimeric and full-length growth hormone receptors by growth hormone receptor monoclonal antibodies. A specific conformational change may be required for full-length receptor signaling. J. Biol. Chem. 273, 5307-5314 CrossRef PubMed
39. Wan, Y., Zheng, Y. Z., Harris, J. M., Brown, R. and Waters, M. J. (2003) Epitope map for a growth hormone receptor agonist monoclonal antibody, MAb 263. Mol. Endocrinol. 17, 2240-2250 CrossRef PubMed
40. Ross, R. J., Leung, K. C., Maamra, M., Bennett, W., Doyle, N., Waters, M. J. and Ho, K. K. (2001) Binding and functional studies with the growth hormone receptor antagonist, B2036-PEG (pegvisomant), reveal effects of pegylation and evidence that it binds to a receptor dimer. J. Clin. Endocrinol. Metab. 86, 1716-1723 PubMed
41. Constantinescu, S. N., Keren, T., Socolovsky, M., Nam, H., Henis, Y. I. and Lodish, H. F. (2001) Ligand-independent oligomerization of cell-surface erythropoietin receptor is mediated by the transmembrane domain. Proc. Natl. Acad. Sci. U.S.A. 98, 4379-4384CrossRef PubMed
42. Kubatzky, K. F., Ruan, W., Gurezka, R., Cohen, J., Ketteler, R., Watowich, S. S., Neumann, D., Langosch, D. and Klingmuller, U. (2001) Self assembly of the transmembrane domain promotes signal transduction through the erythropoietin receptor. Curr. Biol. 11, 110-115 CrossRef PubMed
43. Langosch, D., Brosig, B., Kolmar, H. and Fritz, H. J. (1996) Dimerisation of the glycophorin A transmembrane segment in membranes probed with the ToxR transcription activator. J. Mol. Biol. 263, 525-530 CrossRef PubMed
44. Brooks, A. J., Dai, W., O'Mara, M. L., Abankwa, D., Chhabra, Y., Pelekanos, R. A., Gardon, O., Tunny, K. A., Blucher, K. M., Morton, C. J. et al. (2014) Mechanism of activation of protein kinase JAK2 by the growth hormone receptor. Science 344,1249783 CrossRef PubMed
45. Pelekanos, R. A. (2007) Determining the mechanism of growth hormone receptor dimerization and activation. PhD Thesis. Institute for Molecular Bioscience, The University of Queensland
46. Xu, J., Zhang, Y., Berry, P. A., Jiang, J., Lobie, P. E., Langenheim, J. F., Chen, W. Y. and Frank, S. J. (2011) Growth hormone signaling in human T47D breast cancer cells: potential role for a growth hormone receptor-prolactin receptor complex. Mol. Endocrinol. 25, 597-610 CrossRef PubMed
47. Livnah, O., Stura, E. A., Middleton, S. A., Johnson, D. L., Jolliffe, L. K. and Wilson, I. A. (1999) Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation. Science 283, 987-990 CrossRef PubMed
48. Ruan, W., Becker, V., Klingmuller, U. and Langosch, D. (2004) The interface between self-assembling erythropoietin receptor transmembrane segments corresponds to a membrane-spanning leucine zipper. J. Biol. Chem. 279, 3273-3279 CrossRef PubMed
49. Gent, J., Van Den Eijnden, M., Van Kerkhof, P. and Strous, G. J. (2003) Dimerization and signal transduction of the growth hormone receptor. Mol. Endocrinol. 17, 967-975CrossRef PubMed
50. Brown, R. J., Adams, J. J., Pelekanos, R. A., Wan, Y., McKinstry, W. J., Palethorpe, K., Seeber, R. M., Monks, T. A., Eidne, K. A., Parker, M. W. and Waters, M. J. (2005) Model for growth hormone receptor activation based on subunit rotation within a receptor dimer. Nat. Struct. Mol. Biol. 12, 814-821 CrossRef PubMed
51. Waters, M. J., Brooks, A. J. and Chhabra, Y. (2014) A new mechanism for growth hormone receptor activation of JAK2, and implications for related cytokine receptors. Jak-Stat. 3, e29569 CrossRef PubMed
52. Behncken, S. N., Billestrup, N., Brown, R., Amstrup, J., Conway-Campbell, B. and Waters, M. J. (2000) Growth hormone (GH)-independent dimerization of GH receptor by a leucine zipper results in constitutive activation. J. Biol. Chem. 275, 17000-17007CrossRef PubMed
53. Ahmed, A. S., Xiong, F., Pang, S. C., He, M. D., Waters, M. J., Zhu, Z. Y. and Sun, Y. H. (2011) Activation of GH signaling and GH-independent stimulation of growth in zebrafish by introduction of a constitutively activated GHR construct. Transgenic Res. 20, 557-567 CrossRef PubMed
54. Patel, N., Herrman, J. M., Timans, J. C. and Kastelein, R. A. (1996) Functional replacement of cytokine receptor extracellular domains by leucine zippers. J. Biol. Chem. 271, 30386-30391 CrossRef PubMed
55. Stuhlmann-Laeisz, C., Lang, S., Chalaris, A., Krzysztof, P., Enge, S., Eichler, J., Klingmuller, U., Samuel, M., Ernst, M., Rose-John, S. and Scheller, J. (2006) Forced dimerization of gp130 leads to constitutive STAT3 activation, cytokine-independent growth, and blockade of differentiation of embryonic stem cells. Mol. Biol. Cell 17, 2986-2995 CrossRef PubMed
56. Seubert, N., Royer, Y., Staerk, J., Kubatzky, K. F., Moucadel, V., Krishnakumar, S., Smith, S. O. and Constantinescu, S. N. (2003) Active and inactive orientations of the transmembrane and cytosolic domains of the erythropoietin receptor dimer. Mol. Cell 12, 1239-1250 CrossRef PubMed
57. Staerk, J., Defour, J. P., Pecquet, C., Leroy, E., Antoine-Poirel, H., Brett, I., Itaya, M., Smith, S. O., Vainchenker, W. and Constantinescu, S. N. (2011) Orientation-specific signalling by thrombopoietin receptor dimers. EMBO J. 30, 4398-4413CrossRef PubMed
58. Staerk, J., Lacout, C., Sato, T., Smith, S. O., Vainchenker, W. and Constantinescu, S. N. (2006) An amphipathic motif at the transmembrane-cytoplasmic junction prevents autonomous activation of the thrombopoietin receptor. Blood 107, 1864-1871CrossRef PubMed
59. Pikman, Y., Lee, B. H., Mercher, T., McDowell, E., Ebert, B. L., Gozo, M., Cuker, A., Wernig, G., Moore, S., Galinsky, I. et al. (2006) MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 3, e270CrossRef PubMed
60. Liu, Y., Berry, P. A., Zhang, Y., Jiang, J., Lobie, P. E., Paulmurugan, R., Langenheim, J. F., Chen, W. Y., Zinn, K. R. and Frank, S. J. (2014) Dynamic analysis of GH receptor conformational changes by split luciferase complementation. Mol. Endocrinol. me 20141153
61. Poger, D. and Mark, A. E. (2010) Turning the growth hormone receptor on: evidence that hormone binding induces subunit rotation. Proteins 78, 1163-1174 CrossRef PubMed
62. Zhang, Y., Jiang, J., Kopchick, J. J. and Frank, S. J. (1999) Disulfide linkage of growth hormone (GH) receptors (GHR) reflects GH-induced GHR dimerization. Association of JAK2 with the GHR is enhanced by receptor dimerization. J. Biol. Chem. 274, 33072-33084 CrossRef PubMed
63. Saharinen, P., Vihinen, M. and Silvennoinen, O. (2003) Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain. Mol. Biol. Cell 14, 1448-1459 CrossRef PubMed
64. Haan, C., Behrmann, I. and Haan, S. (2010) Perspectives for the use of structural information and chemical genetics to develop inhibitors of Janus kinases. J. Cell. Mol. Med. 14, 504-527 PubMed
65. Lu, X., Huang, L. J. and Lodish, H. F. (2008) Dimerization by a cytokine receptor is necessary for constitutive activation of JAK2V617F. J. Biol. Chem. 283, 5258-5266CrossRef PubMed
66. Lu, X., Levine, R., Tong, W., Wernig, G., Pikman, Y., Zarnegar, S., Gilliland, D. G. and Lodish, H. (2005) Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. Proc. Natl. Acad. Sci. U.S.A. 102, 18962-18967CrossRef PubMed
67. Funakoshi-Tago, M., Pelletier, S., Moritake, H., Parganas, E. and Ihle, J. N. (2008) Jak2FERM domain interaction with the erythropoietin receptor regulates Jak2 kinase activity. Mol. Cell. Biol. 28, 1792-1801 CrossRef PubMed
68. Varghese, L. N., Ungureanu, D., Liau, N. P., Young, S. N., Laktyushin, A., Hammaren, H., Lucet, I. S., Nicola, N. A., Silvennoinen, O., Babon, J. J. and Murphy, J. M. (2014)Mechanistic insights into activation and SOCS3-mediated inhibition of myeloproliferative neoplasm-associated JAK2 mutants from biochemical and structural analyses. Biochem. J. 458, 395-405 CrossRef PubMed
69. Koppikar, P., Bhagwat, N., Kilpivaara, O., Manshouri, T., Adli, M., Hricik, T., Liu, F., Saunders, L. M., Mullally, A., Abdel-Wahab, O. et al. (2012) Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature 489, 155-159 CrossRef PubMed
70. Babon, J. J., Lucet, I. S., Murphy, J. M., Nicola, N. A. and Varghese, L. N. (2014) The molecular regulation of Janus kinase (JAK) activation. Biochem. J. 462, 1-13CrossRef PubMed
71. Lupardus, P. J., Ultsch, M., Wallweber, H., Bir Kohli, P., Johnson, A. R. and Eigenbrot, C. (2014) Structure of the pseudokinase-kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition. Proc. Natl. Acad. Sci. U.S.A. 111, 8025-8030 CrossRef PubMed
72. Shan, Y., Gnanasambandan, K., Ungureanu, D., Kim, E. T., Hammaren, H., Yamashita, K., Silvennoinen, O., Shaw, D. E. and Hubbard, S. R. (2014) Molecular basis for pseudokinase-dependent autoinhibition of JAK2 tyrosine kinase. Nat. Struct. Mol. Biol. 21, 579-584 CrossRef PubMed
73. Lucet, I. S., Fantino, E., Styles, M., Bamert, R., Patel, O., Broughton, S. E., Walter, M., Burns, C. J., Treutlein, H., Wilks, A. F. and Rossjohn, J. (2006) The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor. Blood 107, 176-183 CrossRef PubMed
74. Bandaranayake, R. M., Ungureanu, D., Shan, Y., Shaw, D. E., Silvennoinen, O. and Hubbard, S. R. (2012) Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F. Nat. Struct. Mol. Biol. 19, 754-759 CrossRef PubMed
75. Lindauer, K., Loerting, T., Liedl, K. R. and Kroemer, R. T. (2001) Prediction of the structure of human Janus kinase 2 (JAK2) comprising the two carboxy-terminal domains reveals a mechanism for autoregulation. Protein Eng. 14, 27-37 CrossRef PubMed
76. Wan, S. and Coveney, P. V. (2012) Regulation of JAK2 activation by Janus homology 2: evidence from molecular dynamics simulations. J. Chem. Inform. Mod. 52, 2992-3000 CrossRef
77. Wan, X., Ma, Y., McClendon, C. L., Huang, L. J. and Huang, N. (2013) Ab initio modeling and experimental assessment of Janus Kinase 2 (JAK2) kinase-pseudokinase complex structure. PLoS Comput. Biol. 9, e1003022 CrossRef PubMed
78. Lupardus, P. J., Skiniotis, G., Rice, A. J., Thomas, C., Fischer, S., Walz, T. and Garcia, K. C. (2011) Structural snapshots of full-length Jak1, a transmembrane gp130/IL-6/IL-6Ralpha cytokine receptor complex, and the receptor-Jak1 holocomplex. Structure 19, 45-55 CrossRef PubMed
79. Levine, R. L., Pardanani, A., Tefferi, A. and Gilliland, D. G. (2007) Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat. Rev. Cancer 7, 673-683CrossRef PubMed
80. Sonbol, M. B., Firwana, B., Zarzour, A., Morad, M., Rana, V. and Tiu, R. V. (2013)Comprehensive review of JAK inhibitors in myeloproliferative neoplasms. Therap. Adv. Hematol. 4, 15-35 CrossRef
81. Scott, L. M., Tong, W., Levine, R. L., Scott, M. A., Beer, P. A., Stratton, M. R., Futreal, P. A., Erber, W. N., McMullin, M. F., Harrison, C. N. et al. (2007) JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N. Engl. J. Med. 356, 459-468CrossRef PubMed
82. Dymock, B. W., Yang, E. G., Chu-Farseeva, Y. and Yao, L. (2014) Selective JAK inhibitors. Future Med. Chem. 6, 1439-1471 CrossRef PubMed
83. Verstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., DiPersio, J. F., Catalano, J. V., Deininger, M., Miller, C., Silver, R. T. et al. (2012) A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N. Engl. J. Med. 366, 799-807CrossRef PubMed
84. Bhagwat, N., Koppikar, P., Keller, M., Marubayashi, S., Shank, K., Rampal, R., Qi, J., Kleppe, M., Patel, H. J., Shah, S. K. et al. (2014) Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms. Blood 123, 2075-2083CrossRef PubMed
85. Duong, V. H. and Komrokji, R. S. (2014) The role of pacritinib in the management of myelofibrosis. Expert Rev. Hematol. 7, 325-332 CrossRef PubMed
86. Hatzimichael, E., Tsolas, E. and Briasoulis, E. (2014) Profile of pacritinib and its potential in the treatment of hematologic disorders. J. Blood Med. 5, 143-152 CrossRef PubMed
87. Hexner, E., Roboz, G., Hoffman, R., Luger, S., Mascarenhas, J., Carroll, M., Clementi, R., Bensen-Kennedy, D. and Moliterno, A. (2014) Open-label study of oral CEP-701 (lestaurtinib) in patients with polycythaemia vera or essential thrombocythaemia with JAK2-V617F mutation. Brit. J. Haematol. 164, 83-93 CrossRef
88. Lee, E. B., Fleischmann, R., Hall, S., Wilkinson, B., Bradley, J. D., Gruben, D., Koncz, T., Krishnaswami, S., Wallenstein, G. V., Zang, C. et al. (2014) Tofacitinib versus methotrexate in rheumatoid arthritis. N. Engl. J. Med. 370, 2377-2386CrossRef PubMed
89. Spoerl, S., Mathew, N. R., Bscheider, M., Schmitt-Graeff, A., Chen, S., Mueller, T., Verbeek, M., Fischer, J., Otten, V., Schmickl, M. et al. (2014) Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease. Blood 123, 3832-3842 CrossRef PubMed
90. Gadd, S. L. and Clevenger, C. V. (2006) Ligand-independent dimerization of the human prolactin receptor isoforms: functional implications. Mol. Endocrinol. 20, 2734-2746CrossRef PubMed
91. Schutt, A., Zacharias, M., Schneider, N., Horn, S., Grotzinger, J., Rose-John, S. and Schmidt-Arras, D. (2013) gp130 activation is regulated by D2-D3 interdomain connectivity. Biochem. J. 450, 487-496 CrossRef PubMed
92. Tenhumberg, S., Schuster, B., Zhu, L., Kovaleva, M., Scheller, J., Kallen, K. J. and Rose-John, S. (2006) gp130 dimerization in the absence of ligand: preformed cytokine receptor complexes. Biochem. Biophys. Res. Commun. 346, 649-657CrossRef PubMed
93. Xu, Y., Kershaw, N. J., Luo, C. S., Soo, P., Pocock, M. J., Czabotar, P. E., Hilton, D. J., Nicola, N. A., Garrett, T. P. and Zhang, J. G. (2010) Crystal structure of the entire ectodomain of gp130: insights into the molecular assembly of the tall cytokine receptor complexes. J. Biol. Chem. 285, 21214-21218 CrossRef PubMed
94. Hemmann, U., Gerhartz, C., Heesel, B., Sasse, J., Kurapkat, G., Grotzinger, J., Wollmer, A., Zhong, Z., Darnell, Jr JE, Graeve, L. et al. (1996) Differential activation of acute phase response factor/Stat3 and Stat1 via the cytoplasmic domain of the interleukin 6 signal transducer gp130. II. Src homology SH2 domains define the specificity of stat factor activation. J. Biol. Chem. 271, 12999-13007 CrossRef PubMed
95. Ishizaka-Ikeda, E., Fukunaga, R., Wood, W. I., Goeddel, D. V. and Nagata, S. (1993)Signal transduction mediated by growth hormone receptor and its chimeric molecules with the granulocyte colony-stimulating factor receptor. Proc. Natl. Acad. Sci. U.S.A. 90, 123-127 CrossRef PubMed
96. Yang, N., Wang, X., Jiang, J. and Frank, S. J. (2007) Role of the growth hormone (GH) receptor transmembrane domain in receptor predimerization and GH-induced activation. Mol. Endocrinol. 21, 1642-1655 CrossRef PubMed
97. Forbes, L. V., Gale, R. E., Pizzey, A., Pouwels, K., Nathwani, A. and Linch, D. C. (2002)An activating mutation in the transmembrane domain of the granulocyte colony-stimulating factor receptor in patients with acute myeloid leukemia. Oncogene 21, 5981-5989 CrossRef PubMed
98. Pardanani, A., Lasho, T. L., Laborde, R. R., Elliott, M., Hanson, C. A., Knudson, R. A., Ketterling, R. P., Maxson, J. E., Tyner, J. W. and Tefferi, A. (2013) CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia. Leukemia 27, 1870-1873 CrossRef PubMed
99. Liongue, C. and Ward, A. C. (2014) Granulocyte colony-stimulating factor receptor mutations in myeloid malignancy. Front. Oncol. 4, 93 CrossRef PubMed
100. Ding, J., Komatsu, H., Iida, S., Yano, H., Kusumoto, S., Inagaki, A., Mori, F., Ri, M., Ito, A., Wakita, A. et al. (2009) The Asn505 mutation of the c-MPL gene, which causes familial essential thrombocythemia, induces autonomous homodimerization of the c-Mpl protein due to strong amino acid polarity. Blood 114, 3325-3328 CrossRef PubMed
101. Lee, T. S., Kantarjian, H., Ma, W., Yeh, C. H., Giles, F. and Albitar, M. (2011) Effects of clinically relevant MPL mutations in the transmembrane domain revealed at the atomic level through computational modeling. PLoS ONE 6, e23396 CrossRef PubMed
102. Matthews, E. E., Thevenin, D., Rogers, J. M., Gotow, L., Lira, P. D., Reiter, L. A., Brissette, W. H. and Engelman, D. M. (2011) Thrombopoietin receptor activation: transmembrane helix dimerization, rotation, and allosteric modulation. FASEB J. 25, 2234-2244 CrossRef PubMed
103. Liu, W., Kawahara, M., Ueda, H. and Nagamune, T. (2009) The influence of domain structures on the signal transduction of chimeric receptors derived from the erythropoietin receptor. J. Biochem. 145, 575-584 CrossRef PubMed
104. Rowlinson, S. W., Yoshizato, H., Barclay, J. L., Brooks, A. J., Behncken, S. N., Kerr, L. M., Millard, K., Palethorpe, K., Nielsen, K., Clyde-Smith, J. et al. (2008) An agonist-induced conformational change in the growth hormone receptor determines the choice of signalling pathway. Nat. Cell Biol. 10, 740-747 CrossRef PubMed
105. Jin, H., Lanning, N. J. and Carter-Su, C. (2008) JAK2, but not Src family kinases, is required for STAT, ERK, and Akt signaling in response to growth hormone in preadipocytes and hepatoma cells. Mol. Endocrinol. 22, 1825-1841CrossRef PubMed
106. Acosta, J. J., Munoz, R. M., Gonzalez, L., Subtil-Rodriguez, A., Dominguez-Caceres, M. A., Garcia-Martinez, J. M., Calcabrini, A., Lazaro-Trueba, I. and Martin-Perez, J. (2003) Src mediates prolactin-dependent proliferation of T47D and MCF7 cells via the activation of focal adhesion kinase/Erk1/2 and phosphatidylinositol 3-kinase pathways. Mol. Endocrinol. 17, 2268-2282 CrossRef PubMed
107. Fresno Vara, J. A., Carretero, M. V., Geronimo, H., Ballmer-Hofer, K. and Martin-Perez, J. (2000) Stimulation of c-Src by prolactin is independent of Jak2. Biochem. J. 345, 17-24 CrossRef PubMed
108. Chin, H., Arai, A., Wakao, H., Kamiyama, R., Miyasaka, N. and Miura, O. (1998) Lyn physically associates with the erythropoietin receptor and may play a role in activation of the Stat5 pathway. Blood 91, 3734-3745 PubMed
109. Slavova-Azmanova, N. S., Kucera, N., Louw, A., Satiaputra, J., Handoko, A., Singer, P., Stone, L., McCarthy, D. J., Klinken, S. P., Hibbs, M. L. and Ingley, E. (2014) Lyn kinase plays important roles in erythroid expansion, maturation and erythropoietin receptor signalling by regulating inhibitory signalling pathways that control survival. Biochem. J. 459, 455-466 CrossRef PubMed
110. Hallek, M., Neumann, C., Schaffer, M., Danhauser-Riedl, S., von Bubnoff, N., de Vos, G., Druker, B. J., Yasukawa, K., Griffin, J. D. and Emmerich, B. (1997) Signal transduction of interleukin-6 involves tyrosine phosphorylation of multiple cytosolic proteins and activation of Src-family kinases Fyn, Hck, and Lyn in multiple myeloma cell lines. Exp. Hematol. 25, 1367-1377 PubMed
111. Dahl, M. E., Arai, K. I. and Watanabe, S. (2000) Association of Lyn tyrosine kinase to the GM-CSF and IL-3 receptor common betac subunit and role of Src tyrosine kinases in DNA synthesis and anti-apoptosis. Genes Cells Dev. Mol. Cell. Mech. 5, 143-153 CrossRef
112. Adachi, T., Pazdrak, K., Stafford, S. and Alam, R. (1999) The mapping of the Lyn kinase binding site of the common beta subunit of IL-3/granulocyte-macrophage colony-stimulating factor/IL-5 receptor. J. Immunol. 162, 1496-1501 PubMed
113. Perugini, M., Brown, A. L., Salerno, D. G., Booker, G. W., Stojkoski, C., Hercus, T. R., Lopez, A. F., Hibbs, M. L., Gonda, T. J. and D'Andrea, R. J. (2010) Alternative modes of GM-CSF receptor activation revealed using activated mutants of the common beta-subunit. Blood 115, 3346-3353 CrossRef PubMed
114. Hibbs, M. L. and Harder, K. W. (2006) The duplicitous nature of the Lyn tyrosine kinase in growth factor signaling. Growth Factors (Chur, Switzerland). 24, 137-149CrossRef PubMed
115. Lambert, Q. T., Pradhan, A., Roll, J. D. and Reuther, G. W. (2011) Mutations in the transmembrane and juxtamembrane domains enhance IL27R transforming activity. Biochem. J. 438, 155-164 CrossRef PubMed
116. Lu, X., Gross, A. W. and Lodish, H. F. (2006) Active conformation of the erythropoietin receptor: random and cysteine-scanning mutagenesis of the extracellular juxtamembrane and transmembrane domains. J. Biol. Chem. 281, 7002-7011 CrossRef PubMed
117. Fox, N. E., Lim, J., Chen, R. and Geddis, A. E. (2010) F104S c-Mpl responds to a transmembrane domain-binding thrombopoietin receptor agonist: proof of concept that selected receptor mutations in congenital amegakaryocytic thrombocytopenia can be stimulated with alternative thrombopoietic agents. Exp. Hematol. 38, 384-391CrossRef PubMed
118. Cammett, T. J., Jun, S. J., Cohen, E. B., Barrera, F. N., Engelman, D. M. and Dimaio, D. (2010) Construction and genetic selection of small transmembrane proteins that activate the human erythropoietin receptor. Proc. Natl. Acad. Sci. U.S.A. 107, 3447-3452 CrossRef PubMed